首页 / 院系成果 / 成果详情页

Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial 期刊论文

编号：

68e13d1d-5a1a-4714-a5e7-98d960c8ae37
作者：

Guo, Ye^[1] Shi, Mei^[2] Yang, Ankui^[3] Feng, Jifeng^[4] Zhu, Xiaodong^[5] Choi, YoungJin^[6] Hu, Guoqin^[7] Pan, Jianji^[8] Hu, Chunhong^[9] Luo, Rongcheng^[10] Zhang, Yiping^[11] Zhou, Liang^[12] Cheng, Ying^[13] Luepfert, Christian^[14] Cai, Junliang^[15] Shi, yuankai^[16,17]
语种：

English
期刊：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK ISSN：1043-3074 2015 年 37 卷 8 期 (1081 - 1087) ; AUG
收录：
关键词：

cetuximab Chinese EXTREME trial head and neck cancer recurrent and metastatic squamous cell carcinoma
摘要：

BackgroundThe purpose of this study was to assess the efficacy, safety, and pharmacokinetics of cisplatin-based chemotherapy plus cetuximab as first-line treatment in Chinese and Korean patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). MethodsPatients (n = 68) received cetuximab weekly plus 3-week cycles of cisplatin/5-fluorouracil (5-FU) chemotherapy for up to 6 cycles. The primary endpoint was overall response rate. ResultsThe overall response rate was 55.9%, including 2 complete responses (CRs). Median overall survival (OS) was 12.6 months and median progression-free survival (PFS) was 6.6 months. Grade 3/4 adverse events (AEs) were reported in 41 (60.3%) patients. The safety profile was in line with previous clinical experience. The pharmacokinetic profile was in line with that observed with cetuximab in white and Japanese patients. ConclusionThe efficacy, safety, and pharmacokinetic findings from this study support the use of first-line platinum-based chemotherapy plus cetuximab in Chinese and Korean patients with recurrent and/or metastatic SCCHN ( NCT01177956). (c) 2014 Wiley Periodicals, Inc. Head Neck37: 1081-1087, 2015
推荐引用方式
GB/T 7714：

Guo Ye,Shi Mei,Yang Ankui, et al. Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial [J].HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK,2015,37(8):1081-1087.
APA：

Guo Ye,Shi Mei,Yang Ankui,Feng Jifeng,&Shi yuankai.(2015).Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial .HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK,37(8):1081-1087.
MLA：

Guo Ye, et al. "Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial" .HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 37,8(2015):1081-1087.

浏览次数：3  下载次数：0

分享到：

浏览次数：3

下载次数：0

打印次数：0